Search Results for: capricor

Capricor seeks FDA approval of deramiocel for Duchenne based on encouraging data

Linda Marbán, Capricor

The cell therapy biotech Capricor recently released new data from their Duchenne Muscular Dystrophy (DMD) trial work. The data have generated excitement in the patient advocacy community. The stock has skyrocketed. How exciting are these new data? CEO Linda Marbán is quite upbeat and I think it’s justified. The firm is now seeking FDA approval […]

Capricor seeks FDA approval of deramiocel for Duchenne based on encouraging data Read More »

Shot to the heart: J&J punts on Capricor & its cardiac stem cell program

Capricor

How is the stem cell and regenerative medicine biotech sector doing these days and does recent news about specific biotechs such as Capricor suggest issues for the sector more broadly? Capricor had bad news earlier this year related to its stem cells for heart disease program and things just took a turn for the worse

Shot to the heart: J&J punts on Capricor & its cardiac stem cell program Read More »

J&J Bets Up to $325 million on Capricor: Big Pharma Stem Cell Move as Predicted for 2014

Big Pharma Giant Johnson & Johnson (J & J; $JNJ) announced today a $12.5 million investment in stem cells & regenerative medicine via the small biotech Capricor ($CAPR) and the potential for the bet to go into the hundreds of millions for the heart disease program. It was only 8 days ago that I made

J&J Bets Up to $325 million on Capricor: Big Pharma Stem Cell Move as Predicted for 2014 Read More »

Poll on stem cell & regenerative medicine good news of 2024

stem cell good news, good news

What are the most significant stem cell and regenerative medicine good news stories of 2024? Since it has been an eventful year, there are many possibilities. Please see our poll at the bottom of this post and weigh in on what you think is the most important encouraging news. If you don’t see your choice

Poll on stem cell & regenerative medicine good news of 2024 Read More »

24 cell therapy & stem cell stocks I’m following

stem cell stocks

Stem cell stocks, meaning cellular therapy biotech companies, face many challenges, but their clinical research is crucial. Stem cell biotechs These biotechs have ups and downs, sometimes at the same time. This is kind of the standard of “life” as any biotech company. It is definitely the case in the volatile stem cell and cell

24 cell therapy & stem cell stocks I’m following Read More »

Review of 4 cell therapy types under study for COVID-19

stem-cells-for-COVID-19-infographic_small

This is a post by Mina Kim, a UC Davis student intern for The Niche blog, about the main types of cellular therapies being studied clinically for COVID-19. During the novel coronavirus pandemic with millions of COVID-19 cases, the development of safe and effective treatments for patients is vital. Cellular medicine treatments are one of

Review of 4 cell therapy types under study for COVID-19 Read More »

COVID-19 cellular medicine buzz: Mesoblast, FTC hammer, more

cell therapy for COVID

  It’s been a busy week for the cellular and regenerative medicine space for COVID-19 news with some possible ups including for Mesoblast and some definite downs. Starting with the more positive media buzz with have Mesoblast. Mesoblast made COVID19 news “Thinly traded Mesoblast Limited (NASDAQ:MESO) rockets 51% premarket on average volume in reaction to its announcement of an

COVID-19 cellular medicine buzz: Mesoblast, FTC hammer, more Read More »